ALK's EURneffy, the first and only approved needle-free nasal adrenaline spray indicated for anaphylaxis, drew attention at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Istanbul after the company presented findings from two multi-country surveys pointing to significant gaps in real-world emergency allergy management. The data suggest that practical and psychological barriers — not just access — are limiting effective treatment at the point of reaction.
The surveys, generated by ALK, document shortcomings in how patients and caregivers deploy epinephrine during anaphylactic events. Needle aversion, device complexity under stress, and failure to carry auto-injectors consistently are among the administration challenges the research identifies. EURneffy's intranasal delivery format is positioned as a mechanism-level intervention: eliminating the injection step may reduce hesitation latency at a moment when speed of administration is the primary clinical endpoint. Bioavailability data supporting nasal-route epinephrine delivery have been foundational to EURneffy's regulatory approval pathway in Europe.
For operators working across the functional foods, nutraceutical, and allergen-management categories, the broader context matters. Food-induced anaphylaxis — driven by peanut, tree nut, shellfish, and increasingly sesame allergens — remains a persistent risk environment that intersects directly with the food-as-medicine supply chain. Brands formulating with common allergenic proteins, developing free-from SKUs, or targeting consumers managing IgE-mediated conditions are operating in a market where emergency preparedness tools are gaining visibility. The global epinephrine auto-injector market has been tracking growth on the back of rising food allergy prevalence, and needle-free alternatives represent a meaningful patient-experience differentiator. Coverage of adjacent allergen and immune-health innovation has been tracked across immune health and clinical nutrition verticals.
From a channel perspective, EURneffy's profile is relevant to health-system purchasers, specialty pharmacy, and the growing direct-to-consumer allergy management segment. As food allergy awareness campaigns continue to drive consumer education, finished-formulation brands in the free-from and allergen-disclosure space may find co-marketing or educational partnership opportunities with pharmaceutical allergen management tools gaining regulatory and clinical momentum in Europe and beyond. Distribution and operator strategy insights in adjacent categories have been explored in functional ingredients coverage on this network.
This reporting is produced in partnership with Food & Beverage Magazine.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.